Rank#3,185of 3,449
MicrosoftExpandedEvidence: Medium50/100

PAREXEL accelerates drug development and clinical innovation with Microsoft Azure

Use case typeAI development platformUpdated Jun 13, 2026

PAREXEL International, a global biopharmaceutical services organization, partnered with Microsoft to advance digital transformation and clinical innovation in the life sciences industry. The alliance focuses on migrating PAREXEL’s informatics technology to Microsoft Azure, combining PAREXEL’s drug development expertise with Microsoft’s cloud infrastructure. The partnership delivers secure, scalable cloud services and drives development of patient-centric technologies. Objectives include improving patient engagement, increasing clinical trial accessibility, and supporting precision medicine using Azure’s robust security, compliance, and global reach.

Organization
PAREXEL International
Industry
Pharma
Location
United States
Published
October 2017

Reported outcomes

Strategic outcomes

Speed & agilityAccelerated clinical research and drug developmentCustomer experience & trustEnhanced patient engagement in trialsScale & capacityIncreased scalability and reliability of R&D platformsNew product / capabilityEnabled patient-centric precision medicine solutions
Why do we believe this deployment?Customer identity, provider attribution, maturity, and source checks
Customer
PAREXEL International
Provider
Microsoft
Maturity
Unknown
Linked source
news.microsoft.com

No explicit deployment-stage evidence found.

Customer identity supportedSource describes one deploymentMaturity evidence evaluated

Primary read

Use case focus

Showing 3 of 3

  • 1digital drug development
  • 2cloud-enabled clinical trials
  • 3patient engagement platform
  • Drug development timelines are lengthy and complex.
  • Clinical trial participation remains challenging for patients.
  • The need to improve regulatory compliance and data accessibility.
  • Industry under pressure to deliver patient-centered solutions faster.
  • Migrated PAREXEL's informatics technology and services to Microsoft Azure.
  • Jointly developed cloud-based services for clinical research.
  • Leveraged Azure’s security, compliance, and global scale.
  • Built solutions to enhance patient engagement and enable precision medicine.
Technologies
AzureAzure AI
  • Accelerated clinical research and drug development timelines.
  • Enhanced patient engagement in clinical trials.
  • Increased scalability, security, and reliability of digital R&D platforms.
  • Supported innovation in precision medicine.
Sources & evidence1
Evidence: Medium50/100Evidence strength
  • Customer explicitly identified
  • Independent source available
  • Technical implementation details available
  • Recent evidence check available
  • Last evidence check: Jun 1, 2026.
ExpandedExpanded

The same organization appears in newer AI deployment evidence.

  • Same organization re-documented as recently as 2026.
  • Cited source last checked Jun 1, 2026 — ok (0/1 broken).

Measures whether this deployment's public evidence persists — not whether the system is still in production.

Type: News ArticlePublished: Oct 24, 2017Publisher: news.microsoft.comEvidence: SecondaryConfidence: Low
Primary source

AI-generated summary. Verify important details with the linked sources before relying on this case.

Explore related AI use cases
Customer evidence
More from PAREXEL International
Provider evidence
Microsoft provider pageMicrosoft ranked cases
Market context
Pharma AI use casesPharma industry insightsUnited States country insights
Browse the catalog
All AI use casesAI use-case typesAI development platform use cases

Was this useful?

Community

Comments

No published comments yet.